RAPT Therapeutics, Inc. (RAPT) EPS (Weighted Average and Diluted) (2021 - 2024)
RAPT Therapeutics' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at $7.08 for Q4 2024.
- For Q4 2024, EPS (Weighted Average and Diluted) rose 974.07% year-over-year to $7.08; the TTM value through Dec 2024 reached -$3.19, down 4.59%, while the annual FY2024 figure was -$3.19, 4.59% down from the prior year.
- EPS (Weighted Average and Diluted) for Q4 2024 was $7.08 at RAPT Therapeutics, up from -$3.79 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $7.08 in Q4 2024 and bottomed at -$5.69 in Q2 2024.
- The 4-year median for EPS (Weighted Average and Diluted) is -$0.66 (2023), against an average of -$0.71.
- The largest YoY upside for EPS (Weighted Average and Diluted) was 974.07% in 2024 against a maximum downside of 762.12% in 2024.
- A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.61 in 2021, then fell by 6.56% to -$0.65 in 2022, then dropped by 24.62% to -$0.81 in 2023, then skyrocketed by 974.07% to $7.08 in 2024.
- Per Business Quant, the three most recent readings for RAPT's EPS (Weighted Average and Diluted) are $7.08 (Q4 2024), -$3.79 (Q3 2024), and -$5.69 (Q2 2024).